This Oncotarget study confirms the upregulation of TERT in primary glioblastomas while all GABP proteins rise with the malignancy of the gliomas.
Taken together these Oncotarget findings show that the CTD and OD domains of mtp53 R273H play critical roles in mutant p53 GOF that pertain to processes associated with DNA replication.
St. Jude Children's Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient's cancer.
Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station.
Last year, the American Cancer Society (ACS) issued an updated set of guidelines for cervical cancer screening - emphasizing the shift toward screening with primary human papillomavirus (HPV) testing. While the ACS recommendation accounts for a transition period to implement primary HPV screening, additional factors should be considered to operationalize these guidelines, according to a special white paper in the July issue of the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer.
A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of The Journal of Nuclear Medicine.
MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology.
Researchers at Washington State University have recently identified a DNA region known as VNTR2-1 that appears to drive the activity of the telomerase gene, which has been shown to prevent aging in certain types of cells. Knowing how the telomerase gene is regulated and activated and why it is only active in certain cell types could someday be the key to understanding how humans age and how to stop the spread of cancer.
A collaboration led by St. Jude Children's Research Hospital, Shanghai Children's Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.